Search

Your search keyword '"Peer, Avivit"' showing total 237 results
Start Over Author "Peer, Avivit"
237 results on '"Peer, Avivit"'

2. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study

Author

Cicin, Irfan, Plimack, Elizabeth R., Gurney, Howard, Leibowitz, Raya, Alekseev, Boris Y., Parnis, Francis X., Peer, Avivit, Necchi, Andrea, Bellmunt, Joaquim, Nishiyama, Hiroyuki, Clark, Jason, Munteanu, Mihaela, Kataria, Ritesh, Jia, Calvin, Powles, Thomas, and Sternberg, Cora N.

Published
2024
Full Text
View/download PDF

4. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial.

Author

Petrylak, Daniel, de Wit, Ronald, Chi, Kim, Drakaki, Alexandra, Sternberg, Cora, Nishiyama, Hiroyuki, Castellano, Daniel, Hussain, Syed, Fléchon, Aude, Bamias, Aristotelis, Yu, Evan, van der Heijden, Michiel, Matsubara, Nobuaki, Alekseev, Boris, Necchi, Andrea, Géczi, Lajos, Ou, Yen-Chuan, Coskun, Hasan, Su, Wen-Pin, Bedke, Jens, Gakis, Georgios, Percent, Ivor, Lee, Jae-Lyun, Tucci, Marcello, Semenov, Andrey, Laestadius, Fredrik, Peer, Avivit, Tortora, Giampaolo, Safina, Sufia, Garcia Del Muro, Xavier, Rodriguez-Vida, Alejo, Cicin, Irfan, Harputluoglu, Hakan, Tagawa, Scott, Vaishampayan, Ulka, Aragon-Ching, Jeanny, Hamid, Oday, Liepa, Astra, Wijayawardana, Sameera, Russo, Francesca, Walgren, Richard, Zimmermann, Annamaria, Hozak, Rebecca, Bell-McGuinn, Katherine, and Powles, Thomas

Subjects
Aged, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Transitional Cell, Docetaxel, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Invasiveness, Neoplasm Metastasis, Platinum, Prognosis, Salvage Therapy, Survival Rate, Urologic Neoplasms, Ramucirumab
Abstract

BACKGROUND: Ramucirumab-an IgG1 vascular endothelial growth factor receptor 2 antagonist-plus docetaxel was previously reported to improve progression-free survival in platinum-refractory, advanced urothelial carcinoma. Here, we report the secondary endpoint of overall survival results for the RANGE trial. METHODS: We did a randomised, double-blind, phase 3 trial in patients with advanced or metastatic urothelial carcinoma who progressed during or after platinum-based chemotherapy. Patients were enrolled from 124 investigative sites (hospitals, clinics, and academic centres) in 23 countries. Previous treatment with one immune checkpoint inhibitor was permitted. Patients were randomly assigned (1:1) using an interactive web response system to receive intravenous ramucirumab 10 mg/kg or placebo 10 mg/kg volume equivalent followed by intravenous docetaxel 75 mg/m2 (60 mg/m2 in Korea, Taiwan, and Japan) on day 1 of a 21-day cycle. Treatment continued until disease progression, unacceptable toxicity, or other discontinuation criteria were met. Randomisation was stratified by geographical region, Eastern Cooperative Oncology Group performance status at baseline, and visceral metastasis. Progression-free survival (the primary endpoint) and overall survival (a key secondary endpoint) were assessed in the intention-to-treat population. The study is registered with ClinicalTrials.gov, NCT02426125; patient enrolment is complete and the last patient on treatment is being followed up for safety issues. FINDINGS: Between July 20, 2015, and April 4, 2017, 530 patients were randomly allocated to ramucirumab plus docetaxel (n=263) or placebo plus docetaxel (n=267) and comprised the intention-to-treat population. At database lock (March 21, 2018) for the final overall survival analysis, median follow-up was 7·4 months (IQR 3·5-13·9). In our sensitivity analysis of investigator-assessed progression-free survival at the overall survival database lock, median progression-free survival remained significantly improved with ramucirumab compared with placebo (4·1 months [95% CI 3·3-4·8] vs 2·8 months [2·6-2·9]; HR 0·696 [95% CI 0·573-0·845]; p=0·0002). Median overall survival was 9·4 months (95% CI 7·9-11·4) in the ramucirumab group versus 7·9 months (7·0-9·3) in the placebo group (stratified HR 0·887 [95% CI 0·724-1·086]; p=0·25). Grade 3 or worse treatment-related treatment-emergent adverse events in 5% or more of patients and with an incidence more than 2% higher with ramucirumab than with placebo were febrile neutropenia (24 [9%] of 258 patients in the ramucirumab group vs 16 [6%] of 265 patients in the placebo group) and neutropenia (17 [7%] of 258 vs six [2%] of 265). Serious adverse events were similar between groups (112 [43%] of 258 patients in the ramucirumab group vs 107 [40%] of 265 patients in the placebo group). Adverse events related to study treatment and leading to death occurred in eight (3%) patients in the ramucirumab group versus five (2%) patients in the placebo group. INTERPRETATION: Additional follow-up supports that ramucirumab plus docetaxel significantly improves progression-free survival, without a significant improvement in overall survival, for patients with platinum-refractory advanced urothelial carcinoma. Clinically meaningful benefit might be restricted in an unselected population. FUNDING: Eli Lilly and Company.

Published
2020

5. Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry

Author

Bjartell, Anders, Costa, Luis, Kramer, Gero, Zurawski, Bogdan, Galli, Luca, Werbrouck, Patrick, Ecke, Thorsten, Parikh, Omi, Bennamoun, Mostefa, Garcia Freire, Camilo, Peer, Avivit, Ljungberg, Börje, Cicin, Irfan, Smith, Emma, Lukac, Martin, Wapenaar, Robert, and Chowdhury, Simon

Published
2022
Full Text
View/download PDF

7. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial

Author

Parnis, Francis, Joshua, Anthony M., Horvath, Lisa G., Steer, Christopher, Marx, Gavin, Sandhu, Shahneen, Gurney, Howard, Ferguson, Thomas, Van Bruwaene, Siska, Luyten, Daisy, Schatteman, Peter, Lumen, Nicolaas, Dirix, Luc, Goeminne, Jean-Charles, Gil, Thierry, Seront, Emmanuel, Vulsteke, Christof, Kussumoto, Celio, Franke, Fabio A., Martinelli de Oliveira, Fabricio Augusto, Pereira de Santana Gomes, Andrea Juliana, Pinczowski, Hélio, Preto, Daniel D'Almeida, Zucca, Luis Eduardo, Borges, Giuliano Santos, Murad, Andre M., Saad, Fred, Chi, Kim N., Fradet, Yves, Fleshner, Neil E., Emmenegger, Urban, Brasso, Klaus, Fizazi, Karim, Culine, Stephane, Thiery-Vuillemin, Antoine, Joly, Florence, Fléchon, Aude, Hilgers, Werner, Eymard, Jean-Christophe, Borchiellini, Delphine, Barthélémy, Philippe, Berger, Raanan, Leibowitz-Amit, Raya, Mermershtain, Wilmosh, Rouvinov, Keren, Peer, Avivit, Kovel, Svetlana, Sella, Avishay, Lolkema, Martijn P., van den Eertwegh, Alfonsus J.M., Voortman, Johannes, Aarts, Maureen J., Gietema, Jourik A., Kim, Choung-Soo, Choi, Young-Deuk, Chung, Byung-Ha, Gafanov, Rustem A., Kopyltsov, Evgeniy, Usynin, Evgeny A., Carles, Joan, Mellado, Begoña, Maroto, José Pablo, García-Donás, Jesús, Rodríguez Moreno, Juan Francisco, Durán, Ignacio, Pérez-Valderrama, Begoña, Castro, Elena, Olmos, David, Méndez-Vidal, María José, Estellés, David Lorente, Sarrió, Regina Gironés, Muñoz-Langa, José, Herranz, Urbano Anido, Puente Vázquez, Javier, Castellanos, Enrique, Hellström, Martin, Widmark, Anders, Lissbrant, Ingela Franck, Jellvert, Åsa, Külich, Cecilia, Blom, René, Ståhl, Olof, Chiang, Po-Hui, Kang, Chih-Hsiung, Ou, Yen-Chuan, Wang, Shian-Shiang, Wu, Hsi-Chin, Lu, Yu-Chuan, Attard, Gerhardt, Khoo, Vincent, Bahl, Amit, Kellati, Prasad, Parikh, Omi, Srinivasan, Rajaguru, Lester, Jason F., Staffurth, John N., Cheng, Heather H., Efstathiou, Eleni, Pilié, Patrick G., George, Daniel J., Karsh, Lawrence I., Kelly, W. Kevin, Danila, Daniel C., Sieber, Paul R., Smith, Matthew R., Heath, Elisabeth I., Vaishampayan, Ulka N., Flaig, Thomas W., Emamekhoo, Hamid, Pinski, Jacek K., Kalebasty, Arash Rezazadeh, Maly, Joseph J., Moon, Helen, Smith, Matthew R, Scher, Howard I, Lara, Primo N, Jr, Yu, Evan Y, George, Daniel J, Chi, Kim N, Danila, Daniel C, Mason, Gary E, Espina, Byron M, Zhao, Xin, Urtishak, Karen A, Francis, Peter, and Lopez-Gitlitz, Angela

Published
2022
Full Text
View/download PDF

8. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study

Author

Necchi, Andrea, Loriot, Yohann, Park, Se Hoon, Tagawa, Scott, Flechon, Aude, Alexeev, Boris, Varlamov, Sergey, Huddart, Robert, Burgess, Earle, Rezazadeh, Arash, Siefker-Radtke, Arlene, Vano, Yann, Gasparro, Donatello, Hamzaj, Alketa, Kopyltsov, Eugeniy, Gracia Donas, Jesus, Mellado, Begona, Parikh, Omi, Schatteman, Peter, Culine, Stephane, Houédé, Nadine, Zanetta, Sylvie, Facchini, Gaetano, Scagliotti, Giorgio, Schinzari, Giovanni, Lee, Jae Lyun, Shkolnik, Mikhail, Fleming, Mark, Joshi, Monica, O'Donnell, Peter, Stöger, Herbert, Decaestecker, Karel, Dirix, Luc, Machiels, Jean Pascal, Borchiellini, Dephine, Delva, Remy, Rolland, Frederic, Hadaschik, Boris, Retz, Margitta, Rosenbaum, Eli, Basso, Umberto, Mosca, Alessandra, Lee, Hyo Jin, Shin, Dong Bok, Cebotaru, Cristina, Duran, Ignacio, Moreno, Victor, Perez Gracia, Jose Luis, Pinto, Alvaro, Su, Wen-Pin, Wang, Shian-Shiang, Hainsworth, John, Schnadig, Ian, Srinivas, Sandhya, Vogelzang, Nicholas, Loidl, Wolfgang, Meran, Johannes, Gross Goupil, Marine, Joly, Florence, Imkamp, Florian, Klotz, Theodor, Krege, Susanne, May, Matthias, Schultze-Seemann, Wolfgang, Strauss, Arne, Zimmermann, Uwe, Keizman, Daniel, Peer, Avivit, Sella, Avishai, Berardi, Rossana, De Giorgi, Ugo, Sternberg, Cora Nanette, Rha, Sun Young, Bulat, Iurie, Izmailov, Adel, Matveev, Vsevolod, Vladimirov, Vladimir, Carles, Joan, Font, Albert, Saez, Maribel, Syndikus, Isabel, Tarver, Kathryn, Appleman, Leonard, Burke, John, Dawson, Nancy, Jain, Sharad, Zakharia, Yousef, Siefker-Radtke, Arlene O, García-Donas, Jesús, Huddart, Robert A, Burgess, Earle F, Fleming, Mark T, Rezazadeh Kalebasty, Arash, Mellado, Begoña, Varlamov, Sergei, Joshi, Monika, Tagawa, Scott T, Akapame, Sydney, Santiago-Walker, Ademi E, Monga, Manish, and O'Hagan, Anne

Published
2022
Full Text
View/download PDF

9. Quantitative circulating tumor DNA (ctDNA) assessment in patients (pts) with advanced urothelial carcinoma (UC) treated with pembrolizumab (pembro) or platinum-based chemotherapy (chemo) from the phase 3 KEYNOTE-361 trial.

Author

Powles, Thomas, primary, Chang, Wayne Yen-Hwa, additional, Yamamoto, Yoshiaki, additional, Muñoz-Langa, José, additional, Reyes, Felipe, additional, Peer, Avivit, additional, Yu, Evan Y., additional, Cohen, Graham, additional, Lorch, Anja, additional, Bavle, Abhishek, additional, Homet Moreno, Blanca, additional, Markensohn, Julia, additional, Edmondson, Mackenzie, additional, Chen, Cai, additional, Cristescu, Razvan, additional, Pena, Carol Elaine, additional, Lunceford, Jared, additional, and Gunduz, Seyda, additional

Published
2024
Full Text
View/download PDF

10. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Author

Cascallar, Diana Vera, Varela, Mirta, Lazzaro, Mauricio Fernandez, Kaen, Diego Lucas, Gatica, Gabriela, Flores, David Hugo, Falco, Agustin, Molina, Matias, Van Aelst, Filip, Vulsteke, Christof, Sautois, Brieuc, Machiels, Jean-Pascal, Schallier, Denis, Brust, Leandro, Rapatoni, Liane, Azevedo, Sergio J, Marinho, Gisele, Soares, Joao Paulo Holanda, Dzik, Carlos, Almeida Silva, Jamile, Fay, Andre Poisl, Gingerich, Joel, Fradet, Yves, Ferrario, Cristiano, Potvin, Kylea, Vanhuyse, Marie, Abdelsalam, Mahmoud, Cheng, Susanna, Caglevic, Christian, Reyes, Felipe, Leal, Jose Luis, Francisco, Francisco, Ibanez, Carolina, Joly, Florence, Laguerre, Brigitte, Ladoire, Sylvain, Flechon, Aude, Topart, Delphine, Huillard, Olivier, Oudard, Stéphane, Gross-Goupil, Marine, Culine, Stephane, Loriot, Yohann, Gravis, Gwenaelle, Reichardt, Peter, Retz, Margitta, Herden, Jan, Pfister, David, Ohlman, Carsten, Stoeckle, Michael, Wirth, Manfred, Lorch, Anja, Niegisch, Guenter, Goebell, Peter J, Boegemann, Martin, Merseburger, Axel, Gakis, Georgios, Bedke, Jens, Neisius, Andreas, Thomas, Christian, Hoefner, Thomas, Telekes, Andras, Kosa, Judit Erzsebet, Revesz, Janos, Bodoky, Gyorgy, Csoszi, Tibor, Csejtei, Andras, Geczi, Lajos, Ruzsa, Agnes, Kolonics, Zsuzsanna, Erfan, Jozsef, McDermott, Ray, Bambury, Richard, Sella, Avishay, Frank, Stephen Jay, Kejzman, Daniel, Goldman, Olesya, Rosenbaum, Eli, Peer, Avivit, Berger, Raanan, Rouvinov, Keren, Sarid, David, Fukasawa, Satoshi, Arai, Gaku, Yamaguchi, Akito, Yokomizo, Akira, Takayama, Tatsuya, Kinoshita, Hidefumi, Kikuchi, Eiji, Mizuno, Ryuichi, Fujii, Yasuhisa, Sassa, Naoto, Matsukawa, Yoshihisa, Fujimoto, Kiyohide, Matsubara, Nobuaki, Tanikawa, Toshiki, Tomita, Yoshihiko, Nishimura, Kazuo, Tsujihata, Masao, Oyama, Masafumi, Masumori, Naoya, Kanayama, Hiroomi, Takano, Toshimi, Miura, Yuji, Miyazaki, Jun, Joraku, Akira, Kimura, Tomokazu, Yamamoto, Yoshiaki, Kobayashi, Kazuki, De Wit, Ronald, Aarts, Maureen, Gerritsen, Winald, Los, Maartje, Beerepoot, Laurens, Izmailov, Adel, Gorelov, Sergey Igorevich, Alekseev, Boris Yakovlevich, Semenov, Andrey, Kostorov, Vladimir Anatolyevich, Alekseev, Sergey M, Zyryanov, Alexander, Oschepkov, Vasiliy Nikolaevich, Shidin, Vladimir Aleksandrovich, Vladimirov, Vladimir Ivanovich, Gafanov, Rustem Airatovich, Karlov, Petr Alexandrovich, Anderson, David Brian, Shepherd, Lucinda, Cohen, Graham Lawrence, Rapoport, Bernardo Louis, Ruff, Paul, Lee, Nari, Bae, Woo Kyun, Lee, Hyo Jin, Herranz, Urbano Anido, Rodriguez-Vida, Alejo, Morales Barrera, Rafael, Grande, Enrique, Alonso Gordoa, Teresa, Guma Padro, Josep, Gauna, Daniel Castellano, Arranz, Jose Angel, Munoz Langa, Jose, Sarrio, Regina Girones, Montesa Pino, Alvaro, Juan Fita, Maria Jose, Su, Yu-Li, Lin, Yung-Chang, Su, Wen-Pin, Shen, Ying-Chun, Chang, Yen-Hwa, Huang, Yi-Hsiu, Sriuranpong, Virote, Chansriwong, Phichai, Srimuninnimit, Vichien, Danchaivijitr, Pongwut, Abali, Huseyin, Yavuz, Sinan, Ozyilkan, Ozgur, Sendur, Mehmet Ali Nahit, Ekenel, Meltem, Ozguroglu, Mustafa, Arslan, Cagatay, Gunduz, Seyda, Ozdogan, Mustafa, Birtle, Alison, Powles, Thomas, Huddart, Robert, de Santis, Maria, Zarkar, Anjali, Evans, Linda, Hussain, Syed, DiSimone, Christopher, Muina, Antonio F, Schlegel, Peter, Jhangiani, Haresh S, Harrison, Michael, Slater, Dennis E, Wright, David, Percent, Ivor J, Lin, Jianqing, Hwang, Clara, Mamtani, Ronac, Gupta, Sumati, Bajaj, Madhuri, Galamaga, Robert, Eklund, John, Wallace, James, Shtivelband, Mikhail, Suh, Jason Jung-Gon, Burhani, Nafisa, Eadens, Matthew, Gunturu, Krishna, Burgess, Earle, Wong, John, Chaudhry, Arvind, Van Veldhuizen, Peter, Graff, Stephanie, Thomas, Christian A, Schnadig, Ian D, Carneiro, Benedito, Hussain, Maha, Morgans, Alicia, Fitzharris, John T, Oliff, Ira A, Vuky, Jacqueline, Hauke, Ralph, Baron, Ari, Joshi, Monika, Bolemon, Britt H, Jiang, Peter, Mega, Anthony E, Markus, Maurice, Pfanzelter, Nicklas, Lawler, William Eyre, Cobb, Patrick Wayne, Courtright, Jay G, Jain, Sharad, Doshi, Gurjyot, Gunuganti, Vijay K, Sartor, Oliver Alton, Cole, Scott W, Babiker, Hani, Uchio, Edward M, Drakaki, Alexandra, Mannuel, Heather D, Alva, Ajjai, Guancial, Elizabeth, Fung, Chunkit, Charles, Anthony, Amato, Robert J, Arriaga, Yull, Bowman, Isaac, Ades, Steven, Dreicer, Robert, Yu, Evan, Quinn, David I, Fleming, Mark, Csőszi, Tibor, Özgüroğlu, Mustafa, Géczi, Lajos, Cheng, Susanna Y-S, Oudard, Stephane, Fléchon, Aude, Yu, Evan Y, Nam, Kijoeng, Imai, Kentaro, and Homet Moreno, Blanca

Published
2021
Full Text
View/download PDF

11. Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma:results from the ECHO-307/KEYNOTE-672 study

Author

Necchi, Andrea, Van der Heijden, Michiel S., Trukhin, Dmytro, Peer, Avivit, Gurney, Howard, Alekseev, Boris Y., Parnis, Francis X., Leibowitz, Raya, De Santis, Maria, Grivas, Petros, Clark, Jason, Munteanu, Mihaela, Kataria, Ritesh, Jia, Calvin, Balar, Arjun V., de Wit, Ronald, Necchi, Andrea, Van der Heijden, Michiel S., Trukhin, Dmytro, Peer, Avivit, Gurney, Howard, Alekseev, Boris Y., Parnis, Francis X., Leibowitz, Raya, De Santis, Maria, Grivas, Petros, Clark, Jason, Munteanu, Mihaela, Kataria, Ritesh, Jia, Calvin, Balar, Arjun V., and de Wit, Ronald

Abstract

Background: Indoleamine 2,3- dioxygenase 1 (IDO1) is an immunosuppressive enzyme that has been correlated with shorter disease-specific survival in patients with urothelial carcinoma (UC). IDO1 may counteract the antitumor effects of immune checkpoint inhibitors. Epacadostat is a potent and highly selective inhibitor of IDO1. In the phase I/II ECHO-202/KEYNOTE-037 study, epacadostat plus pembrolizumab resulted in a preliminary objective response rate (ORR) of 35% in a cohort of patients with advanced UC. Methods: ECHO-307/KEYNOTE-672 was a double-blinded, randomized, phase III study. Eligible adults had confirmed locally advanced/unresectable or metastatic UC of the urinary tract and were ineligible to receive cisplatin-based chemotherapy. Participants were randomly assigned (1:1) to receive epacadostat (100 mg twice daily) plus pembrolizumab (200 mg every 3 weeks) or placebo plus pembrolizumab for up to 35 pembrolizumab infusions. The primary endpoint was investigator-assessed ORR per Response Evaluation Criteria in Solid Tumors (version 1.1). Results: A total of 93 patients were randomized (epacadostat plus pembrolizumab, n = 44; placebo plus pembrolizumab, n = 49). Enrollment was stopped early due to emerging data from the phase III ECHO-301/KEYNOTE-252 study. The median duration of follow-up was 64 days in both arms. Based on all available data at cutoff, ORR (unconfirmed) was 31.8% (95% CI, 22.46–55.24%) for epacadostat plus pembrolizumab and 24.5% (95% CI, 15.33–43.67%) for placebo plus pembrolizumab. Circulating kynurenine levels numerically increased from C1D1 to C2D1 in the placebo-plus-pembrolizumab arm and decreased in the epacadostat-plus-pembrolizumab arm. Epacadostat-plus-pembrolizumab combination treatment was well tolerated with a safety profile similar to the placebo arm. Treatment discontinuations due to treatment-related adverse events were more frequent with epacadostat (11.6% vs. 4.1%). Conclusions: Treatment with epacadostat plus pembrolizum

Published
2024

12. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Author

Park, Se Hoon, van der Heijden, Michiel S., Necchi, Andrea, Castellano, Daniel, Bamias, Aristotelis, Lee, Jae Lyun, De Giorgi, Ugo, Bögemann, Martin, Eigl, Bernhard J., Tsiatas, Marinos, Powles, Thomas, Novikov, Andrey, Skoneczna, Iwona, Mukherjee, Som D., Suarez, Cristina, Westgeest, Hans, Fradet, Yves, Flechon, Aude, Ou, Yen-Chuan, Park, Inkeun, Matveev, Vsevolod, Pérez-Valderrama, Begoña, Cheng, Susanna, Frank, Stephen, Gurney, Howard, Anido, Urbano, Hamzaj, Alketa, Retz, Margitta, Sridhar, Srikala, Scagliotti, Giorgio Vittorio, Voortman, Jens, Alekseev, Boris, Alyasova, Anna, Komyakov, Boris, Dumez, Herlinde, Pavic, Michel, Kimura, Go, Mizokami, Atsushi, Osanto, Susanne, Arranz, Jose Angel, Piersma, Djura, Shin, Sang Joon, Karyakin, Oleg, Delgado, Ignacio, Gonzalez, Jose Luis, Pang, See-Tong, Tran, Anna, Lipatov, Oleg, Su, Wen-Pin, Flaig, Thomas, Alva, Ajjai, Park Kyong, Hwa, Kopyltsov, Evgeny, Almagro, Elena, Domenech, Monserrat, Chang, Yen-Hwa, Sautois, Brieuc, Ravaux, Andre, Aravantinos, Gerasimos, Georgoulias, Vasileios, Mulder, Sasja, Kim, Yu Jung, Kater, Fabio, Chevreau, Christine, Tagawa, Scott, Zalewski, Pawel, Joly, Florence, Loriot, Yohann, Hatiboglu, Gencay, Gianni, Luca, Morelli, Franco, Tambaro, Rosa, Hashimoto, Yasuhiro, Nosov, Alexander, Font, Albert, Rodriguez-Vida, Alejo M., Jones, Robert, Vasudev, Naveen, Srinivas, Sandhya, Zhang, Jingsong, Gil, Thierry, Finch, Daygen, Grimm, Marc-Oliver, Su, Yu-Li, Chowdhury, Simon, Hocking, Christopher, Plas, Eugen, North, Scott, Jensen, Niels Viggo, Theodore, Christine, Imkamp, Florian, Peer, Avivit, Kobayashi, Takashi, Sakai, Hideki, Sassa, Naoto, Yoshimura, Kazuhiro, Aarts, Maureen, Ferreira Castro, Ana, Topuzov, Marlen, Rodriguez, Juan Francisco, Vazquez, Federico Jose, Tsai, Yu-Chieh, Crabb, Simon, Hussain, Syed, Bendell, Johanna, Gross-Goupil, Marine, Gwenaelle, Gravis, Berger, Raanan, Statsenko, Galina, Evans, Linda, Drakaki, Alexandra, Somer, Bradley, Davis, Ian, Lynam, James, Borges, Giuliano, Dettino, Aldo, Fay, André P., Martins, Graziella, Zucca, Luis Eduardo, Agerbaek, Mads, Kalofonos, Haralambos, Rosenbaum, Eli, Enokida, Hideki, Kikukawa, Hiroaki, Nishimura, Kazuo, Tamada, Satoshi, Uemura, Motohide, Lopez, Yamil, Gietema, Jourik, Slojewski, Marcin, Fernandes, Isabel, Smolin, Alexey, Mazhar, Danish, Kalebasty, Arash Rezazadeh, Carthon, Bradley, Loidl, Wolfgang, Franke, Fabio, Girotto, Gustavo, Alimohamed, Nimira, Macfarlane, Robyn, Pappot, Helle, Niegisch, Guenter, Mavroudis, Dimitrios, Sella, Avishay, Porta, Camillo, Ebara, Shin, Nakamura, Motonobu, Obara, Wataru, Okuno, Norihiko, Shinohara, Nobuo, Sugimoto, Mikio, Suzuki, Akitaka, Tokuda, Noriaki, Uemura, Hiroji, Yamaguchi, Akito, Ramirez, Francisco, Rozanowski, Pawel, Wiechno, Pawel, Keam, Bhumsuk, Kislov, Nikolay, Plaksin, Denis, Cicin, Irfan, Kumar, Satish, Galsky, Matthew D., Petrylak, Daniel P., Rosales, Joseph, Vaishampayan, Ulka, Culine, Stephane, Papandreou, Christos, Nara, Taketoshi, Erman, Mustafa, Kreiger, Laurence, Janoski, Juliana, Rosa, Diogo, Siqueira, Mariana, Canil, Christina, Sengelov, Lisa, Tourani, Jean-Marc, Arai, Gaku, Hashine, Katsuyoshi, Kawakita, Mutsushi, Nakaigawa, Noboru, Nomi, Hayahito, Shiina, Hiroaki, Suzuki, Hiroyoshi, Yonese, Junji, Kuri, Roberto, Macedo, Eleazar, Rivera, Samuel, Villalobos Prieto, Alberto, Polakiewicz-Gilowska, Anna, Zaucha, Renata, Lopes, Fabio, Ponomarev, Roman, Pomerantz, Mark, Shariat, Shahrokh, Luk, Cynthia, Lesniewski-Kmak, Krzysztof, van der Heijden, Michiel S, Galsky, Matthew D, Petrylak, Daniel P, Ogawa, Osamu, Lee, Jae-Lyun, Eigl, Bernhard J, Mukherjee, Som D, Suárez, Cristina, Fay, André P, Duran, Ignacio, Wildsmith, Sophie, He, Philip, Angra, Natasha, Gupta, Ashok K, Levin, Wendy, and Bellmunt, Joaquim

Published
2020
Full Text
View/download PDF

13. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

Author

Wong, Suet-Lai Shirley, Tan, Thean Hsiang, Hovey, Elizabeth Jane, Clay, Timothy Dudley, Wan Ng, Siobhan Su, Rutten, Annemie, Machiels, Jean-Pascal, Dumez, Herlinde, Cheng, Susanna Yee-Shan, Ferrario, Cristiano, Sengeloev, Lisa, Jensen, Niels Viggo, Thibault, Constance, Laguerre, Brigitte, Joly, Florence, Culine, Stéphane, Becht, Catherine, Niegisch, Günter, Stöckle, Michael, Grimm, Marc-Oliver, Schwentner, Christina A, Schultze-Seemann, Wolfgang, Kalofonos, Haralambos, Mavroudis, Dimitrios, Papandreou, Christos, Karavasilis, Vasilis, Révész, Janos, Rosenbaum, Eli, Leibowitz-Amit, Raya, Kejzman, Daniel, Sarid, David, Scagliotti, Giorgio Vittorio, Bracarda, Sergio, Massari, Francesco, Osawa, Takahiro, Miyajima, Naoto, Shinohara, Nobuo, Fukuta, Fumimasa, Ohyama, Chikara, Obara, Wataru, Yamashita, Shinichi, Tomita, Yoshihiko, Kawai, Koji, Fukasawa, Satoshi, Oyama, Masafumi, Yonese, Junji, Nagata, Masayoshi, Uemura, Motohide, Nishimura, Kazuo, Kawakita, Mutsushi, Tsunemori, Hiroyuki, Hashine, Katsuyoshi, Inokuchi, Junichi, Yokomizo, Akira, Nagamori, Satoshi, Lee, Hyo Jin, Park, Se Hoon, Rha, Sun Young, Kim, Yu Jung, Lee, Yun-Gyoo, Vazquez Cortés, Leticia, Lorena Urzua Flores, Claudia, Blaisse, Reinoud J.B., Erdkamp, Fransiscus L.G., Aarts, Maureen J.B., Wojcik-Tomaszewska, Joanna, Tomczak, Piotr, Sikora-Kupis, Bozena, Schenker, Michael, Herzal, Alina Amalia, Udrea, Anghel Adrian, Karlov, Petr, Fomkin, Roman, Gajate Borau, Pablo, Grande, Enrique, Delgado Mignorance, Juan Ignacio, Su, Yu-Li, Li, Jian-Ri, Lin, Chien-Liang, Lin, Chia-Chi, Yeh, Su-Peng, Erman, Mustafa, Urun, Yuksel, Golovko, Yuriy, Bondarenko, Igor, Sinielnikov, Ivan, Crabb, Simon J., Syndikus, Isabel, Huddart, Robert, Sundar, Santhanam, Chowdhury, Simon, Sarwar, Naveed, Flaig, Thomas W., Pan, Chong Xian, Schwarz, James K., Cultrera, Jennifer Lyn, Acs, Peter Istvan, Hainsworth, John D., Herms, Benjamin T., Lawler, William Eyre, Lowe, Thomas Eugene, Petrylak, Daniel P, de Wit, Ronald, Chi, Kim N, Drakaki, Alexandra, Sternberg, Cora N, Nishiyama, Hiroyuki, Castellano, Daniel, Hussain, Syed A, Fléchon, Aude, Bamias, Aristotelis, Yu, Evan Y, van der Heijden, Michiel S, Matsubara, Nobuaki, Alekseev, Boris, Necchi, Andrea, Géczi, Lajos, Ou, Yen-Chuan, Coskun, Hasan Senol, Su, Wen-Pin, Bedke, Jens, Gakis, Georgios, Percent, Ivor J, Lee, Jae-Lyun, Tucci, Marcello, Semenov, Andrey, Laestadius, Fredrik, Peer, Avivit, Tortora, Giampaolo, Safina, Sufia, Garcia del Muro, Xavier, Rodriguez-Vida, Alejo, Cicin, Irfan, Harputluoglu, Hakan, Tagawa, Scott T, Vaishampayan, Ulka, Aragon-Ching, Jeanny B, Hamid, Oday, Liepa, Astra M, Wijayawardana, Sameera, Russo, Francesca, Walgren, Richard A, Zimmermann, Annamaria H, Hozak, Rebecca R, Bell-McGuinn, Katherine M, and Powles, Thomas

Published
2020
Full Text
View/download PDF

17. Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Long-Term Results of a Prospective Phase II Study

Author

Keizman, Daniel, primary, Frenkel, Moshe, additional, Peer, Avivit, additional, Rosenbaum, Eli, additional, Sarid, David, additional, Leibovitch, Ilan, additional, Mano, Roy, additional, Yossepowitch, Ofer, additional, Wolf, Ido, additional, Geva, Ravit, additional, Margel, David, additional, Rouvinov, Keren, additional, Stern, Anat, additional, Dresler, Hadas, additional, Kushnir, Igal, additional, and Eliaz, Isaac, additional

Published
2023
Full Text
View/download PDF

18. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

Author

Wong, Suet-Lai Shirley, Tan, Thean Hsiang, Hovey, Elizabeth Jane, Clay, Timothy Dudley, Ng, Siobhan Su Wan, Rutten, Annemie, Machiels, Jean-Pascal, Dumez, Herlinde, Cheng, Susanna Yee-Shan, Chi, Kim Nguyen, Ferrario, Cristiano, Sengeloev, Lisa, Jensen, Niels Viggo, Thibault, Constance, Laguerre, Brigitte, Laestadius, Fredrik, Joly, Florence, Flechon, Aude, Culine, Stéphane, Becht, Catherine, Niegisch, Günter, Stöckle, Michael, Grimm, Marc-Oliver, Gakis, Georgios, Schultze-Seemann, Wolfgang, Kalofonos, Haralambos, Mavroudis, Dimitrios, Papandreou, Christos, Karavasilis, Vasilis, Bamias, Aristotelis, Révész, Janos, Geczi, Lajos, Rosenbaum, Eli, Leibowitz-Amit, Raya, Kejzman, Daniel, Peer, Avivit, Sarid, David, Scagliotti, Giorgio Vittorio, Sternberg, Cora N, Tortora, Giampaolo, Bracarda, Sergio, Necchi, Andrea, Massari, Francesco, Osawa, Takahiro, Miyajima, Naoto, Shinohara, Nobuo, Fukuta, Fumimasa, Ohyama, Chikara, Obara, Wataru, Yamashita, Shinichi, Tomita, Yoshihiko, Kawai, Koji, Fukasawa, Satoshi, Matsubara, Nobuaki, Oyama, Masafumi, Yonese, Junji, Nagata, Masayoshi, Uemura, Motohide, Nishimura, Kazuo, Kawakita, Mutsushi, Tsunemori, Hiroyuki, Hashine, Katsuyoshi, Inokuchi, Junichi, Yokomizo, Akira, Nagamori, Satoshi, Lee, Jae-Lyun, Lee, Hyo Jin, Park, Se Hoon, Rha, Sun Young, Kim, Yu Jung, Lee, Yun-Gyoo, Cortés, Leticia Vazquez, Flores, Claudia Lorena Urzua, Blaisse, Reinoud J B, van der Heijden, Michiel S, de Wit, Ronald, Erdkamp, Fransiscus L G, Aarts, Maureen J B, Wojcik-Tomaszewska, Joanna, Tomczak, Piotr, Sikora-Kupis, Bozena, Schenker, Michael, Herzal, Alina Amalia, Udrea, Anghel Adrian, Karlov, Petr, Safina, Sufia Z, Alekseev, Boris, Semenov, Andrey, Fomkin, Roman, Pulido, Enrique Grande, Del Muro, F Xavier García, Mignorance, Juan Ignacio Delgado, Gauna, Daniel Castellano, Rodríguez-Vida, Alejo, Su, Yu-Li, Ou, Yen-Chuan, Lin, Chien-Liang, Su, Wen-Pin, Lin, Chia-Chi, Yeh, Su-Peng, Çiçin, Irfan, Harputluoglu, Hakan, Erman, Mustafa, Coskun, Hasan Senol, Urun, Yuksel, Golovko, Yurii, Bondarenko, Igor, Sinielnikov, Ivan, Powles, Thomas, Crabb, Simon, Syndikus, Isabel, Huddart, Robert, Sundar, Santhanam, Chowdhury, Simon, Sarwar, Naveed, Drakaki, Alexandra, Flaig, Thomas, Pan, Chong Xian, Petrylak, Daniel, Schwarz, James, Percent, Ivor, Cultrera, Jennifer, Hainsworth, John, Herms, Benjamin, Lawler, William, Lowe, Thomas, Tagawa, Scott, Aragon-Ching, Jeanny, Vaishampayan, Ulka, Petrylak, Daniel P, Chi, Kim N, Nishiyama, Hiroyuki, Castellano, Daniel, Hussain, Syed, Fléchon, Aude, Yu, Evan Y, Géczi, Lajos, Hegemann, Miriam, Percent, Ivor J, Tucci, Marcello, Safina, Sufia, del Muro, Xavier Garcia, Rodriguez-Vida, Alejo, Cicin, Irfan, Widau, Ryan C, Liepa, Astra M, Walgren, Richard A, Hamid, Oday, Zimmermann, Annamaria H, and Bell-McGuinn, Katherine M

Published
2017
Full Text
View/download PDF

19. Network meta-analysis (NMA) to assess comparative efficacy of lenvatinib plus pembrolizumab compared with other first-line treatments for management of advanced renal cell carcinoma (aRCC).

Author

Grünwald, Viktor, Winquist, Eric, Peer, Avivit, Schmidinger, Manuela, Procopio, Giuseppe, Barthelemy, Philippe, Lee, Jae-Lyun, Rudman, Sarah, Kadambi, Ananth, Pandey, Anuja, Neupane, Binod, Fahrbach, Kyle, Purushotham, Sneha, Jones, Michael, Egodage, Sonya, Kashyap, Ananth, Hauck, Wendy, and Pan, Janice

Published
2024
Full Text
View/download PDF

23. Erdafitinib treatment in metastatic urothelial carcinoma: a real-world analysis

Author

Rouvinov, Keren, primary, Levanon, Eran, additional, Peer, Avivit, additional, Sarfaty, Michal, additional, Sarid, David, additional, Neiman, Victoria, additional, Grikshtas, Eduard, additional, Rosenbaum, Eli, additional, Kushnir, Igal, additional, Talmor, Barak, additional, Friger, Michael, additional, Zarbiv, Yonaton, additional, Gez, Eli, additional, Dresler, Hadas, additional, Shalata, Walid, additional, Meirovitz, Amichay, additional, Shrem, Noa Shani, additional, Yakobson, Alexander, additional, Mermershtain, Wilmosh, additional, and Keizman, Daniel, additional

Published
2023
Full Text
View/download PDF

25. Data from Six-Month Efficacy and Toxicity Profile of BNT162b2 Vaccine in Cancer Patients with Solid Tumors

Author

Waldhorn, Ithai, primary, Holland, Roy, primary, Goshen-Lago, Tal, primary, Shirman, Yelena, primary, Szwarcwort-Cohen, Moran, primary, Reiner-Benaim, Anat, primary, Shachor-Meyouhas, Yael, primary, Hussein, Khetam, primary, Fahoum, Liana, primary, Peer, Avivit, primary, Almog, Ronit, primary, Shaked, Yuval, primary, Halberthal, Michael, primary, and Ben-Aharon, Irit, primary

Published
2023
Full Text
View/download PDF

26. Supplementary Data from Six-Month Efficacy and Toxicity Profile of BNT162b2 Vaccine in Cancer Patients with Solid Tumors

Author

Waldhorn, Ithai, primary, Holland, Roy, primary, Goshen-Lago, Tal, primary, Shirman, Yelena, primary, Szwarcwort-Cohen, Moran, primary, Reiner-Benaim, Anat, primary, Shachor-Meyouhas, Yael, primary, Hussein, Khetam, primary, Fahoum, Liana, primary, Peer, Avivit, primary, Almog, Ronit, primary, Shaked, Yuval, primary, Halberthal, Michael, primary, and Ben-Aharon, Irit, primary

Published
2023
Full Text
View/download PDF

28. Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study

Author

Graff, Julie N., Hoimes, Christopher J., Gerritsen, Winald R., Vaishampayan, Ulka N., Elliott, Tony, Hwang, Clara, ten Tije, Albert J., Omlin, Aurelius, McDermott, Raymond S., Fradet, Yves, Tagawa, Scott T., Kilari, Deepak, Ferrario, Cristiano, Uemura, Hiroji, Jones, Robert J., Fukasawa, Satoshi, Peer, Avivit, Niu, Cuizhen, Poehlein, Christian H., Qiu, Ping, Suttner, Leah, de Wit, Ronald, Schloss, Charles, de Bono, Johann S., and Antonarakis, Emmanuel S.

Abstract

Background: KEYNOTE-199 (NCT02787005) is a multicohort phase 2 study evaluating pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC). Results from cohorts 4 (C4) and 5 (C5) are presented. Methods: Eligible patients had not received chemotherapy for mCRPC and had responded to enzalutamide prior to developing resistance as defined by Prostate Cancer Clinical Trials Working Group 3 guidelines. Patients with RECIST-measurable disease were enrolled in C4, and patients with bone-only or bone-predominant disease were enrolled in C5. All patients received pembrolizumab 200 mg every 3 weeks for ≤35 cycles with ongoing enzalutamide until progression, unacceptable toxicity, or withdrawal. The primary end point was objective response rate (ORR) per RECIST v1.1 by blinded independent central review in C4. Secondary end points included disease control rate (DCR), overall survival, and safety in each cohort and both cohorts combined. Results: A total of 126 patients were treated (C4, n= 81; C5, n= 45). Median age was 72 years (range 43–92), and 87.3% had received ≥6 months of enzalutamide prior to study entry. Confirmed ORR was 12.3% (95% CI 6.1–21.5%) for C4. Median duration of response in C4 was 8.1 months (range, 2.5+ to 15.2), and 5 of these patients experienced an objective response lasting ≥6 months. DCR was 53.1% (95% CI 41.7–64.3%) in C4 and 51.1% (95% CI 35.8–66.3%) in C5. Median overall survival was 17.6 months (95% CI 14.0–22.6) in C4 and 20.8 months (95% CI 14.1–28.9) in C5. Grade ≥3 treatment-related adverse events occurred in 35 patients (27.8%); 2 patients in C4 died from immune-related adverse events (myasthenic syndrome and Guillain-Barré syndrome). Conclusions: The addition of pembrolizumab to ongoing enzalutamide treatment in patients with mCRPC that progressed on enzalutamide after initial response demonstrated modest antitumor activity with a manageable safety profile. Clinical trial registry and ID: ClinicalTrials.gov, NCT02787005.

Published
2024
Full Text
View/download PDF

29. Treatment of muscle-invasive urothelial cancer with nivolumab (CheckMate 274 study): a plain language summary

Author

Bajorin, Dean F, primary, Witjes, J Alfred, additional, Gschwend, Jürgen E, additional, Schenker, Michael, additional, Valderrama, Begoña P, additional, Tomita, Yoshihiko, additional, Bamias, Aristotelis, additional, Lebret, Thierry, additional, Shariat, Shahrokh F., additional, Park, Se Hoon, additional, Ye, Dingwei, additional, Agerbaek, Mads, additional, Enting, Deborah, additional, McDermott, Ray, additional, Gajate, Pablo, additional, Peer, Avivit, additional, Milowsky, Matthew I, additional, Nosov, Alexander, additional, Antonio, João Neif, additional, Tupikowski, Krzysztof, additional, Toms, Laurence, additional, Fischer, Bruce S, additional, Qureshi, Anila, additional, Collette, Sandra, additional, Unsal-Kacmaz, Keziban, additional, Broughton, Edward, additional, Zardavas, Dimitrios, additional, Koon, Henry B, additional, and Galsky, Matthew D, additional

Published
2023
Full Text
View/download PDF

30. P-MCP treatment in non-metastatic biochemically relapsed prostate cancer (BRPC-M0): Final long-term results of a prospective phase II study.

Author

Keizman, Daniel, primary, Frenkel, Moshe A., additional, Peer, Avivit, additional, Kushnir, Igal, additional, Rosenbaum, Eli, additional, Sarid, David Leonid, additional, Leibovitch, Ilan, additional, Mano, Roy, additional, Yossepowitch, Ofer, additional, Margel, David, additional, Wolf, Ido, additional, Geva, Ravit, additional, Rouvinov, Keren, additional, Dresler, Hadas, additional, and Eliaz, Isaac, additional

Published
2023
Full Text
View/download PDF

34. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study

Author

UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Centre du cancer, UCL - (SLuc) Unité d'oncologie médicale, Siefker-Radtke, Arlene O, Necchi, Andrea, Park, Se Hoon, García-Donas, Jesús, Huddart, Robert A, Burgess, Earle F, Fleming, Mark T, Rezazadeh Kalebasty, Arash, Mellado, Begoña, Varlamov, Sergei, Joshi, Monika, Duran, Ignacio, Tagawa, Scott T, Zakharia, Yousef, Akapame, Sydney, Santiago-Walker, Ademi E, Monga, Manish, O'Hagan, Anne, Loriot, Yohann, Tagawa, Scott, Flechon, Aude, Alexeev, Boris, Varlamov, Sergey, Huddart, Robert, Burgess, Earle, Rezazadeh, Arash, Siefker-Radtke, Arlene, Vano, Yann, Gasparro, Donatello, Hamzaj, Alketa, Kopyltsov, Eugeniy, Gracia Donas, Jesus, Mellado, Begona, Parikh, Omi, Schatteman, Peter, Culine, Stephane, Houédé, Nadine, Zanetta, Sylvie, Facchini, Gaetano, Scagliotti, Giorgio, Schinzari, Giovanni, Lee, Jae Lyun, Shkolnik, Mikhail, Fleming, Mark, Joshi, Monica, O'Donnell, Peter, Stöger, Herbert, Decaestecker, Karel, Dirix, Luc, Machiels, Jean Pascal, Borchiellini, Dephine, Delva, Remy, Rolland, Frederic, Hadaschik, Boris, Retz, Margitta, Rosenbaum, Eli, Basso, Umberto, Mosca, Alessandra, Lee, Hyo Jin, Shin, Dong Bok, Cebotaru, Cristina, Moreno, Victor, Perez Gracia, Jose Luis, Pinto, Alvaro, Su, Wen-Pin, Wang, Shian-Shiang, Hainsworth, John, Schnadig, Ian, Srinivas, Sandhya, Vogelzang, Nicholas, Loidl, Wolfgang, Meran, Johannes, Gross Goupil, Marine, Joly, Florence, Imkamp, Florian, Klotz, Theodor, Krege, Susanne, May, Matthias, Schultze-Seemann, Wolfgang, Strauss, Arne, Zimmermann, Uwe, Keizman, Daniel, Peer, Avivit, Sella, Avishai, Berardi, Rossana, De Giorgi, Ugo, Sternberg, Cora Nanette, Rha, Sun Young, Bulat, Iurie, Izmailov, Adel, Matveev, Vsevolod, Vladimirov, Vladimir, Carles, Joan, Font, Albert, Saez, Maribel, Syndikus, Isabel, Tarver, Kathryn, Appleman, Leonard, Burke, John, Dawson, Nancy, Jain, Sharad, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Centre du cancer, UCL - (SLuc) Unité d'oncologie médicale, Siefker-Radtke, Arlene O, Necchi, Andrea, Park, Se Hoon, García-Donas, Jesús, Huddart, Robert A, Burgess, Earle F, Fleming, Mark T, Rezazadeh Kalebasty, Arash, Mellado, Begoña, Varlamov, Sergei, Joshi, Monika, Duran, Ignacio, Tagawa, Scott T, Zakharia, Yousef, Akapame, Sydney, Santiago-Walker, Ademi E, Monga, Manish, O'Hagan, Anne, Loriot, Yohann, Tagawa, Scott, Flechon, Aude, Alexeev, Boris, Varlamov, Sergey, Huddart, Robert, Burgess, Earle, Rezazadeh, Arash, Siefker-Radtke, Arlene, Vano, Yann, Gasparro, Donatello, Hamzaj, Alketa, Kopyltsov, Eugeniy, Gracia Donas, Jesus, Mellado, Begona, Parikh, Omi, Schatteman, Peter, Culine, Stephane, Houédé, Nadine, Zanetta, Sylvie, Facchini, Gaetano, Scagliotti, Giorgio, Schinzari, Giovanni, Lee, Jae Lyun, Shkolnik, Mikhail, Fleming, Mark, Joshi, Monica, O'Donnell, Peter, Stöger, Herbert, Decaestecker, Karel, Dirix, Luc, Machiels, Jean Pascal, Borchiellini, Dephine, Delva, Remy, Rolland, Frederic, Hadaschik, Boris, Retz, Margitta, Rosenbaum, Eli, Basso, Umberto, Mosca, Alessandra, Lee, Hyo Jin, Shin, Dong Bok, Cebotaru, Cristina, Moreno, Victor, Perez Gracia, Jose Luis, Pinto, Alvaro, Su, Wen-Pin, Wang, Shian-Shiang, Hainsworth, John, Schnadig, Ian, Srinivas, Sandhya, Vogelzang, Nicholas, Loidl, Wolfgang, Meran, Johannes, Gross Goupil, Marine, Joly, Florence, Imkamp, Florian, Klotz, Theodor, Krege, Susanne, May, Matthias, Schultze-Seemann, Wolfgang, Strauss, Arne, Zimmermann, Uwe, Keizman, Daniel, Peer, Avivit, Sella, Avishai, Berardi, Rossana, De Giorgi, Ugo, Sternberg, Cora Nanette, Rha, Sun Young, Bulat, Iurie, Izmailov, Adel, Matveev, Vsevolod, Vladimirov, Vladimir, Carles, Joan, Font, Albert, Saez, Maribel, Syndikus, Isabel, Tarver, Kathryn, Appleman, Leonard, Burke, John, Dawson, Nancy, and Jain, Sharad

Abstract

Background Erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, was shown to be clinically active and tolerable in patients with advanced urothelial carcinoma and prespecified FGFR alterations in the primary analysis of the BLC2001 study at median 11 months of follow-up. We aimed to assess the long-term efficacy and safety of the selected regimen of erdafitinib determined in the initial part of the study. Methods The open-label, non-comparator, phase 2, BLC2001 study was done at 126 medical centres in 14 countries across Asia, Europe, and North America. Eligible patients were aged 18 years or older with locally advanced and unresectable or metastatic urothelial carcinoma, at least one prespecified FGFR alteration, an Eastern Cooperative Oncology Group performance status of 0–2, and progressive disease after receiving at least one systemic chemotherapy or within 12 months of neoadjuvant or adjuvant chemotherapy or were ineligible for cisplatin. The selected regimen determined in the initial part of the study was continuous once daily 8 mg/day oral erdafitinib in 28-day cycles, with provision for pharmacodynamically guided uptitration to 9 mg/day (8 mg/day UpT). The primary endpoint was investigator-assessed confirmed objective response rate according to Response Evaluation Criteria In Solid Tumors version 1.1. Efficacy and safety were analysed in all treated patients who received at least one dose of erdafitinib. This is the final analysis of this study. This study is registered with ClinicalTrials.gov, NCT02365597. Findings Between May 25, 2015, and Aug 9, 2018, 2328 patients were screened, of whom 212 were enrolled and 101 were treated with the selected erdafitinib 8 mg/day UpT regimen. The data cutoff date for this analysis was Aug 9, 2019. Median efficacy follow-up was 24·0 months (IQR 22·7–26·6). The investigator-assessed objective response rate for patients treated with the selected erdafitinib regimen was 40 (40%; 95% CI 30–49

Published
2022

36. Correction: Bar-Sela et al. Cannabis Consumption Used by Cancer Patients during Immunotherapy Correlates with Poor Clinical Outcome. Cancers 2020, 12, 2447

Author

Bar-Sela, Gil, primary, Cohen, Idan, additional, Campisi-Pinto, Salvatore, additional, Lewitus, Gil M., additional, Oz-Ari, Lanuel, additional, Jehassi, Ayellet, additional, Peer, Avivit, additional, Turgeman, Ilit, additional, Vernicova, Olga, additional, Berman, Paula, additional, Wollner, Mira, additional, Moskovitz, Mor, additional, and Meiri, David, additional

Published
2022
Full Text
View/download PDF

37. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial

Author

Smith, Matthew R, primary, Scher, Howard I, additional, Sandhu, Shahneen, additional, Efstathiou, Eleni, additional, Lara, Primo N, additional, Yu, Evan Y, additional, George, Daniel J, additional, Chi, Kim N, additional, Saad, Fred, additional, Ståhl, Olof, additional, Olmos, David, additional, Danila, Daniel C, additional, Mason, Gary E, additional, Espina, Byron M, additional, Zhao, Xin, additional, Urtishak, Karen A, additional, Francis, Peter, additional, Lopez-Gitlitz, Angela, additional, Fizazi, Karim, additional, Parnis, Francis, additional, Joshua, Anthony M., additional, Horvath, Lisa G., additional, Steer, Christopher, additional, Marx, Gavin, additional, Gurney, Howard, additional, Ferguson, Thomas, additional, Van Bruwaene, Siska, additional, Luyten, Daisy, additional, Schatteman, Peter, additional, Lumen, Nicolaas, additional, Dirix, Luc, additional, Goeminne, Jean-Charles, additional, Gil, Thierry, additional, Seront, Emmanuel, additional, Vulsteke, Christof, additional, Kussumoto, Celio, additional, Franke, Fabio A., additional, Martinelli de Oliveira, Fabricio Augusto, additional, Pereira de Santana Gomes, Andrea Juliana, additional, Pinczowski, Hélio, additional, Preto, Daniel D'Almeida, additional, Zucca, Luis Eduardo, additional, Borges, Giuliano Santos, additional, Murad, Andre M., additional, Chi, Kim N., additional, Fradet, Yves, additional, Fleshner, Neil E., additional, Emmenegger, Urban, additional, Brasso, Klaus, additional, Culine, Stephane, additional, Thiery-Vuillemin, Antoine, additional, Joly, Florence, additional, Fléchon, Aude, additional, Hilgers, Werner, additional, Eymard, Jean-Christophe, additional, Borchiellini, Delphine, additional, Barthélémy, Philippe, additional, Berger, Raanan, additional, Leibowitz-Amit, Raya, additional, Mermershtain, Wilmosh, additional, Rouvinov, Keren, additional, Peer, Avivit, additional, Kovel, Svetlana, additional, Sella, Avishay, additional, Lolkema, Martijn P., additional, van den Eertwegh, Alfonsus J.M., additional, Voortman, Johannes, additional, Aarts, Maureen J., additional, Gietema, Jourik A., additional, Kim, Choung-Soo, additional, Choi, Young-Deuk, additional, Chung, Byung-Ha, additional, Gafanov, Rustem A., additional, Kopyltsov, Evgeniy, additional, Usynin, Evgeny A., additional, Carles, Joan, additional, Mellado, Begoña, additional, Maroto, José Pablo, additional, García-Donás, Jesús, additional, Rodríguez Moreno, Juan Francisco, additional, Durán, Ignacio, additional, Pérez-Valderrama, Begoña, additional, Castro, Elena, additional, Méndez-Vidal, María José, additional, Estellés, David Lorente, additional, Sarrió, Regina Gironés, additional, Muñoz-Langa, José, additional, Herranz, Urbano Anido, additional, Puente Vázquez, Javier, additional, Castellanos, Enrique, additional, Hellström, Martin, additional, Widmark, Anders, additional, Lissbrant, Ingela Franck, additional, Jellvert, Åsa, additional, Külich, Cecilia, additional, Blom, René, additional, Chiang, Po-Hui, additional, Kang, Chih-Hsiung, additional, Ou, Yen-Chuan, additional, Wang, Shian-Shiang, additional, Wu, Hsi-Chin, additional, Lu, Yu-Chuan, additional, Attard, Gerhardt, additional, Khoo, Vincent, additional, Bahl, Amit, additional, Kellati, Prasad, additional, Parikh, Omi, additional, Srinivasan, Rajaguru, additional, Lester, Jason F., additional, Staffurth, John N., additional, Cheng, Heather H., additional, Pilié, Patrick G., additional, George, Daniel J., additional, Karsh, Lawrence I., additional, Kelly, W. Kevin, additional, Danila, Daniel C., additional, Sieber, Paul R., additional, Smith, Matthew R., additional, Heath, Elisabeth I., additional, Vaishampayan, Ulka N., additional, Flaig, Thomas W., additional, Emamekhoo, Hamid, additional, Pinski, Jacek K., additional, Kalebasty, Arash Rezazadeh, additional, Maly, Joseph J., additional, and Moon, Helen, additional

Published
2022
Full Text
View/download PDF

38. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study

Author

Siefker-Radtke, Arlene O, primary, Necchi, Andrea, additional, Park, Se Hoon, additional, García-Donas, Jesús, additional, Huddart, Robert A, additional, Burgess, Earle F, additional, Fleming, Mark T, additional, Rezazadeh Kalebasty, Arash, additional, Mellado, Begoña, additional, Varlamov, Sergei, additional, Joshi, Monika, additional, Duran, Ignacio, additional, Tagawa, Scott T, additional, Zakharia, Yousef, additional, Akapame, Sydney, additional, Santiago-Walker, Ademi E, additional, Monga, Manish, additional, O'Hagan, Anne, additional, Loriot, Yohann, additional, Tagawa, Scott, additional, Flechon, Aude, additional, Alexeev, Boris, additional, Varlamov, Sergey, additional, Huddart, Robert, additional, Burgess, Earle, additional, Rezazadeh, Arash, additional, Siefker-Radtke, Arlene, additional, Vano, Yann, additional, Gasparro, Donatello, additional, Hamzaj, Alketa, additional, Kopyltsov, Eugeniy, additional, Gracia Donas, Jesus, additional, Mellado, Begona, additional, Parikh, Omi, additional, Schatteman, Peter, additional, Culine, Stephane, additional, Houédé, Nadine, additional, Zanetta, Sylvie, additional, Facchini, Gaetano, additional, Scagliotti, Giorgio, additional, Schinzari, Giovanni, additional, Lee, Jae Lyun, additional, Shkolnik, Mikhail, additional, Fleming, Mark, additional, Joshi, Monica, additional, O'Donnell, Peter, additional, Stöger, Herbert, additional, Decaestecker, Karel, additional, Dirix, Luc, additional, Machiels, Jean Pascal, additional, Borchiellini, Dephine, additional, Delva, Remy, additional, Rolland, Frederic, additional, Hadaschik, Boris, additional, Retz, Margitta, additional, Rosenbaum, Eli, additional, Basso, Umberto, additional, Mosca, Alessandra, additional, Lee, Hyo Jin, additional, Shin, Dong Bok, additional, Cebotaru, Cristina, additional, Moreno, Victor, additional, Perez Gracia, Jose Luis, additional, Pinto, Alvaro, additional, Su, Wen-Pin, additional, Wang, Shian-Shiang, additional, Hainsworth, John, additional, Schnadig, Ian, additional, Srinivas, Sandhya, additional, Vogelzang, Nicholas, additional, Loidl, Wolfgang, additional, Meran, Johannes, additional, Gross Goupil, Marine, additional, Joly, Florence, additional, Imkamp, Florian, additional, Klotz, Theodor, additional, Krege, Susanne, additional, May, Matthias, additional, Schultze-Seemann, Wolfgang, additional, Strauss, Arne, additional, Zimmermann, Uwe, additional, Keizman, Daniel, additional, Peer, Avivit, additional, Sella, Avishai, additional, Berardi, Rossana, additional, De Giorgi, Ugo, additional, Sternberg, Cora Nanette, additional, Rha, Sun Young, additional, Bulat, Iurie, additional, Izmailov, Adel, additional, Matveev, Vsevolod, additional, Vladimirov, Vladimir, additional, Carles, Joan, additional, Font, Albert, additional, Saez, Maribel, additional, Syndikus, Isabel, additional, Tarver, Kathryn, additional, Appleman, Leonard, additional, Burke, John, additional, Dawson, Nancy, additional, and Jain, Sharad, additional

Published
2022
Full Text
View/download PDF

39. RADIUM-223 RE-TREATMENT: EXPERIENCE FROM AN INTERNATIONAL, MULTICENTER, PROSPECTIVE STUDY IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER AND BONE METASTASES: MP50-16

Author

Nordquist, Luke, Keizman, Daniel, Mariados, Neil, Méndez Vidal, Maria José, Thellenberg-Karlsson, Camilla, Peer, Avivit, Procopio, Giuseppe, Frank, Stephen J., Pulkkanen, Kalevi, Severi, Stefano, Trigo Perez, Jose Manuel, Schwarzenberger, Paul, Li, Rui, and Sartor, Oliver

Published
2016
Full Text
View/download PDF

40. Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Results of a Prospective Phase II Study

Author

Keizman, Daniel, primary, Frenkel, Moshe, additional, Peer, Avivit, additional, Kushnir, Igal, additional, Rosenbaum, Eli, additional, Sarid, David, additional, Leibovitch, Ilan, additional, Mano, Roy, additional, Yossepowitch, Ofer, additional, Margel, David, additional, Wolf, Ido, additional, Geva, Ravit, additional, Dresler, Hadas, additional, Rouvinov, Keren, additional, Rapoport, Noa, additional, and Eliaz, Isaac, additional

Published
2021
Full Text
View/download PDF

41. Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer

Author

Goshen-Lago, Tal, primary, Waldhorn, Ithai, additional, Holland, Roy, additional, Szwarcwort-Cohen, Moran, additional, Reiner-Benaim, Anat, additional, Shachor-Meyouhas, Yael, additional, Hussein, Khetam, additional, Fahoum, Liana, additional, Baruch, Mali, additional, Peer, Avivit, additional, Reiter, Yoram, additional, Almog, Ronit, additional, Halberthal, Michael, additional, and Ben-Aharon, Irit, additional

Published
2021
Full Text
View/download PDF

42. Reply by Authors

Author

Lifshitz, Karin, primary, Ber, Yaara, additional, Shenhar, Chen, additional, Nillson, Jan, additional, Peer, Avivit, additional, Rosenbaum, Eli, additional, Baniel, Jack, additional, Kedar, Daniel, additional, Ben Zadok, Osnat Itzhaki, additional, and Margel, David, additional

Published
2021
Full Text
View/download PDF

43. Cardiovascular Proteomics: A Post Hoc Analysis from a Phase II Randomized Clinical Trial Comparing GnRH Antagonist vs GnRH Agonist among Men with Advanced Prostate Cancer

Author

Lifshitz, Karin, primary, Ber, Yaara, additional, Shenhar, Chen, additional, Nillson, Jan, additional, Peer, Avivit, additional, Rosenbaum, Eli, additional, Baniel, Jack, additional, Kedar, Daniel, additional, Ben Zadok, Osnat Itzhaki, additional, and Margel, David, additional

Published
2021
Full Text
View/download PDF

44. Six-Month Efficacy and Toxicity Profile of BNT162b2 Vaccine in Cancer Patients with Solid Tumors

Author

Waldhorn, Ithai, primary, Holland, Roy, additional, Goshen-Lago, Tal, additional, Shirman, Yelena, additional, Szwarcwort-Cohen, Moran, additional, Reiner-Benaim, Anat, additional, Shachor-Meyouhas, Yael, additional, Hussein, Khetam, additional, Fahoum, Liana, additional, Peer, Avivit, additional, Almog, Ronit, additional, Shaked, Yuval, additional, Halberthal, Michael, additional, and Ben-Aharon, Irit, additional

Published
2021
Full Text
View/download PDF

45. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Author

Powles, Thomas, primary, Csőszi, Tibor, additional, Özgüroğlu, Mustafa, additional, Matsubara, Nobuaki, additional, Géczi, Lajos, additional, Cheng, Susanna Y-S, additional, Fradet, Yves, additional, Oudard, Stephane, additional, Vulsteke, Christof, additional, Morales Barrera, Rafael, additional, Fléchon, Aude, additional, Gunduz, Seyda, additional, Loriot, Yohann, additional, Rodriguez-Vida, Alejo, additional, Mamtani, Ronac, additional, Yu, Evan Y, additional, Nam, Kijoeng, additional, Imai, Kentaro, additional, Homet Moreno, Blanca, additional, Alva, Ajjai, additional, Cascallar, Diana Vera, additional, Varela, Mirta, additional, Lazzaro, Mauricio Fernandez, additional, Kaen, Diego Lucas, additional, Gatica, Gabriela, additional, Flores, David Hugo, additional, Falco, Agustin, additional, Molina, Matias, additional, Van Aelst, Filip, additional, Sautois, Brieuc, additional, Machiels, Jean-Pascal, additional, Schallier, Denis, additional, Brust, Leandro, additional, Rapatoni, Liane, additional, Azevedo, Sergio J, additional, Marinho, Gisele, additional, Soares, Joao Paulo Holanda, additional, Dzik, Carlos, additional, Almeida Silva, Jamile, additional, Fay, Andre Poisl, additional, Gingerich, Joel, additional, Ferrario, Cristiano, additional, Potvin, Kylea, additional, Vanhuyse, Marie, additional, Abdelsalam, Mahmoud, additional, Cheng, Susanna, additional, Caglevic, Christian, additional, Reyes, Felipe, additional, Leal, Jose Luis, additional, Francisco, Francisco, additional, Ibanez, Carolina, additional, Joly, Florence, additional, Laguerre, Brigitte, additional, Ladoire, Sylvain, additional, Flechon, Aude, additional, Topart, Delphine, additional, Huillard, Olivier, additional, Oudard, Stéphane, additional, Gross-Goupil, Marine, additional, Culine, Stephane, additional, Gravis, Gwenaelle, additional, Reichardt, Peter, additional, Retz, Margitta, additional, Herden, Jan, additional, Pfister, David, additional, Ohlman, Carsten, additional, Stoeckle, Michael, additional, Wirth, Manfred, additional, Lorch, Anja, additional, Niegisch, Guenter, additional, Goebell, Peter J, additional, Boegemann, Martin, additional, Merseburger, Axel, additional, Gakis, Georgios, additional, Bedke, Jens, additional, Neisius, Andreas, additional, Thomas, Christian, additional, Hoefner, Thomas, additional, Telekes, Andras, additional, Kosa, Judit Erzsebet, additional, Revesz, Janos, additional, Bodoky, Gyorgy, additional, Csoszi, Tibor, additional, Csejtei, Andras, additional, Geczi, Lajos, additional, Ruzsa, Agnes, additional, Kolonics, Zsuzsanna, additional, Erfan, Jozsef, additional, McDermott, Ray, additional, Bambury, Richard, additional, Sella, Avishay, additional, Frank, Stephen Jay, additional, Kejzman, Daniel, additional, Goldman, Olesya, additional, Rosenbaum, Eli, additional, Peer, Avivit, additional, Berger, Raanan, additional, Rouvinov, Keren, additional, Sarid, David, additional, Fukasawa, Satoshi, additional, Arai, Gaku, additional, Yamaguchi, Akito, additional, Yokomizo, Akira, additional, Takayama, Tatsuya, additional, Kinoshita, Hidefumi, additional, Kikuchi, Eiji, additional, Mizuno, Ryuichi, additional, Fujii, Yasuhisa, additional, Sassa, Naoto, additional, Matsukawa, Yoshihisa, additional, Fujimoto, Kiyohide, additional, Tanikawa, Toshiki, additional, Tomita, Yoshihiko, additional, Nishimura, Kazuo, additional, Tsujihata, Masao, additional, Oyama, Masafumi, additional, Masumori, Naoya, additional, Kanayama, Hiroomi, additional, Takano, Toshimi, additional, Miura, Yuji, additional, Miyazaki, Jun, additional, Joraku, Akira, additional, Kimura, Tomokazu, additional, Yamamoto, Yoshiaki, additional, Kobayashi, Kazuki, additional, De Wit, Ronald, additional, Aarts, Maureen, additional, Gerritsen, Winald, additional, Los, Maartje, additional, Beerepoot, Laurens, additional, Izmailov, Adel, additional, Gorelov, Sergey Igorevich, additional, Alekseev, Boris Yakovlevich, additional, Semenov, Andrey, additional, Kostorov, Vladimir Anatolyevich, additional, Alekseev, Sergey M, additional, Zyryanov, Alexander, additional, Oschepkov, Vasiliy Nikolaevich, additional, Shidin, Vladimir Aleksandrovich, additional, Vladimirov, Vladimir Ivanovich, additional, Gafanov, Rustem Airatovich, additional, Karlov, Petr Alexandrovich, additional, Anderson, David Brian, additional, Shepherd, Lucinda, additional, Cohen, Graham Lawrence, additional, Rapoport, Bernardo Louis, additional, Ruff, Paul, additional, Lee, Nari, additional, Bae, Woo Kyun, additional, Lee, Hyo Jin, additional, Herranz, Urbano Anido, additional, Grande, Enrique, additional, Alonso Gordoa, Teresa, additional, Guma Padro, Josep, additional, Gauna, Daniel Castellano, additional, Arranz, Jose Angel, additional, Munoz Langa, Jose, additional, Sarrio, Regina Girones, additional, Montesa Pino, Alvaro, additional, Juan Fita, Maria Jose, additional, Su, Yu-Li, additional, Lin, Yung-Chang, additional, Su, Wen-Pin, additional, Shen, Ying-Chun, additional, Chang, Yen-Hwa, additional, Huang, Yi-Hsiu, additional, Sriuranpong, Virote, additional, Chansriwong, Phichai, additional, Srimuninnimit, Vichien, additional, Danchaivijitr, Pongwut, additional, Abali, Huseyin, additional, Yavuz, Sinan, additional, Ozyilkan, Ozgur, additional, Sendur, Mehmet Ali Nahit, additional, Ekenel, Meltem, additional, Ozguroglu, Mustafa, additional, Arslan, Cagatay, additional, Ozdogan, Mustafa, additional, Birtle, Alison, additional, Powles, Thomas, additional, Huddart, Robert, additional, de Santis, Maria, additional, Zarkar, Anjali, additional, Evans, Linda, additional, Hussain, Syed, additional, DiSimone, Christopher, additional, Muina, Antonio F, additional, Schlegel, Peter, additional, Jhangiani, Haresh S, additional, Harrison, Michael, additional, Slater, Dennis E, additional, Wright, David, additional, Percent, Ivor J, additional, Lin, Jianqing, additional, Hwang, Clara, additional, Gupta, Sumati, additional, Bajaj, Madhuri, additional, Galamaga, Robert, additional, Eklund, John, additional, Wallace, James, additional, Shtivelband, Mikhail, additional, Suh, Jason Jung-Gon, additional, Burhani, Nafisa, additional, Eadens, Matthew, additional, Gunturu, Krishna, additional, Burgess, Earle, additional, Wong, John, additional, Chaudhry, Arvind, additional, Van Veldhuizen, Peter, additional, Graff, Stephanie, additional, Thomas, Christian A, additional, Schnadig, Ian D, additional, Carneiro, Benedito, additional, Hussain, Maha, additional, Morgans, Alicia, additional, Fitzharris, John T, additional, Oliff, Ira A, additional, Vuky, Jacqueline, additional, Hauke, Ralph, additional, Baron, Ari, additional, Joshi, Monika, additional, Bolemon, Britt H, additional, Jiang, Peter, additional, Mega, Anthony E, additional, Markus, Maurice, additional, Pfanzelter, Nicklas, additional, Lawler, William Eyre, additional, Cobb, Patrick Wayne, additional, Courtright, Jay G, additional, Jain, Sharad, additional, Doshi, Gurjyot, additional, Gunuganti, Vijay K, additional, Sartor, Oliver Alton, additional, Cole, Scott W, additional, Babiker, Hani, additional, Uchio, Edward M, additional, Drakaki, Alexandra, additional, Mannuel, Heather D, additional, Guancial, Elizabeth, additional, Fung, Chunkit, additional, Charles, Anthony, additional, Amato, Robert J, additional, Arriaga, Yull, additional, Bowman, Isaac, additional, Ades, Steven, additional, Dreicer, Robert, additional, Yu, Evan, additional, Quinn, David I, additional, and Fleming, Mark, additional

Published
2021
Full Text
View/download PDF

47. 177Lu-Prostate-Specific Membrane Antigen Ligand After 223Ra Treatment in Men with Bone-Metastatic Castration-Resistant Prostate Cancer: Real-World Clinical Experience

Author

Sartor, Oliver, primary, Fougère, Christian la, additional, Essler, Markus, additional, Ezziddin, Samer, additional, Kramer, Gero, additional, Ellinger, Jörg, additional, Nordquist, Luke, additional, Sylvester, John, additional, Paganelli, Giovanni, additional, Peer, Avivit, additional, Bögemann, Martin, additional, Meltzer, Jeffrey, additional, Sandström, Per, additional, Verholen, Frank, additional, and Song, Daniel Y., additional

Published
2021
Full Text
View/download PDF

48. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma

Author

Bajorin, Dean F., primary, Witjes, J. Alfred, additional, Gschwend, Jürgen E., additional, Schenker, Michael, additional, Valderrama, Begoña P., additional, Tomita, Yoshihiko, additional, Bamias, Aristotelis, additional, Lebret, Thierry, additional, Shariat, Shahrokh F., additional, Park, Se Hoon, additional, Ye, Dingwei, additional, Agerbaek, Mads, additional, Enting, Deborah, additional, McDermott, Ray, additional, Gajate, Pablo, additional, Peer, Avivit, additional, Milowsky, Matthew I., additional, Nosov, Alexander, additional, Neif Antonio, João, additional, Tupikowski, Krzysztof, additional, Toms, Laurence, additional, Fischer, Bruce S., additional, Qureshi, Anila, additional, Collette, Sandra, additional, Unsal-Kacmaz, Keziban, additional, Broughton, Edward, additional, Zardavas, Dimitrios, additional, Koon, Henry B., additional, and Galsky, Matthew D., additional

Published
2021
Full Text
View/download PDF

49. Post hoc analysis of the CLEAR study in advanced renal cell carcinoma (RCC): Effect of subsequent therapy on survival outcomes in the lenvatinib (LEN) + everolimus (EVE) versus sunitinib (SUN) treatment arms.

Author

Hutson, Thomas E., primary, Choueiri, Toni K., additional, Motzer, Robert J., additional, Rha, Sun Young, additional, Alyasova, Anna, additional, Merchan, Jaime R., additional, Gurney, Howard, additional, Peer, Avivit, additional, Takagi, Toshio, additional, Porta, Camillo, additional, Powles, Thomas, additional, Grünwald, Viktor, additional, De Giorgi, Ugo, additional, Vaishampayan, Ulka N., additional, Schmidinger, Manuela, additional, Glen, Hilary, additional, Rodriguez-Lopez, Karla, additional, Xing, Dongyuan, additional, Dutta, Lea, additional, and Eto, Masatoshi, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results